Will Both Parties Support Trump's Domestic Investment?
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
a minute ago
- Forbes
Samsung Makes New $490 Offer To Galaxy S25 Buyers
Samsung released two new discount codes last week for the Galaxy S25 Ultra that knocked 10% off the phone and boosted trade-in prices. Now, the company is back with a $490 double promotion that gives away a free Galaxy Watch while discounting the phone. The deal knocks £150 off ($200.95) an unlocked Galaxy S25 Ultra, which brings the price down to £1,099 ($1472.31) from £1,249 ($1673.26). It's not as cheap as Google's latest Pixel 9 Pro deal, but it's a solid price drop nonetheless. That discount can be combined with a trade-in. Samsung's current trade-in valuations are surprisingly good, with today's prices beating some of the company's best valuations from June. Check out the price comparisons below. If Samsung's valuation for your used phone is decent, it's worth considering locking in that price by using the company's new store credit system via its dedicated trade-in site. These prices change regularly, and Samsung is offering to hold that store credit for five years. Just make sure the trade-in site's price matches the Galaxy S25 purchase page price. The company is also gifting a free Galaxy Watch 7 with all Galaxy S25 Ultra purchases, which is worth £239 ($289.99 in the U.S). This is automatically added to your basket when you buy the Galaxy S25 Ultra and the offer expires on August 12th. Both deals apply to U.K. shoppers. Elsewhere, Samsung is bundling six months of Google AI Pro with Galaxy S25 purchases, which is six months less than Google is giving to Pixel 9 buyers. The device also comes with the standard three months of Samsung Care Plus and 30% off other wearables. Expect More Samsung Deals In The Run Up To Apple's iPhone 17 Launch Samsung won't miss the opportunity to steal some of Apple's iPhone 17 limelight with some aggressive discounts, freebies, or a combination of both. Google's new Pixel 10 ad, that takes an indirect shot at Apple's Siri problems, gives us an insight into how the upcoming smartphone battle will unfold. 'If you buy a phone because of a feature that is coming soon, but it has been coming soon for a full year. You could change your definition of 'soon', or you could just change your phone.' The narrator says over cloaked images of the Pixel 10 while the instrumental to Dr. Dre's The Next Episode plays in the background. The ad is referencing Apple's delayed personalized Siri features that are powered by Apple Intelligence. They were debuted at WWDC 2024 and then used to promote the iPhone 16. But after the phone launched, the company later said that the features would come 'soon,' which sparked a class action lawsuit from iPhone 16 buyers who said they felt misled about the phone's AI abilities. At WWDC this year, Apple said that the promised personalized Siri features will land in 2026, giving Google and Samsung a huge head start with their own mobile AI systems: Gemini and Galaxy AI. I expect both companies will repeatedly point out the iPhone's lack of advanced AI tools and, as a way to entice customers over to the Android side, run more free AI subscription deals. Google is currently bundling one year of AI Pro to all Pixel 9 owners and six months to Galaxy S25 buyers. Samsung also recently gave away a free year's subscription to Perplexity AI Pro, another generative AI chatbot. I wouldn't be surprised if both companies double down on this strategy while Apple scrambles to find its feet in the AI world.
Yahoo
28 minutes ago
- Yahoo
BlinkRx Launches "Operation Access Now" to Accelerate and Scale Direct‑to‑Patient and Direct‑to‑Business Programs
Operation Access Now enables pharmaceutical manufacturers to launch direct‑to‑patient programs within 21 days NEW YORK, August 07, 2025--(BUSINESS WIRE)--BlinkRx, the nation's leading prescription lifecycle management platform, today announced the launch of Operation Access Now, a rapid deployment initiative that enables pharmaceutical manufacturers to build and launch direct-to-patient (DTP) and direct‑to‑business (DTB) channels that expand medication access and deliver pricing transparency in as little as 21 days. This program comes at a moment of growing urgency across the life sciences industry. As traditional access models struggle to meet patient and provider expectations, leading brands are turning to faster, more scalable approaches. BlinkRx's national infrastructure already supports millions of patients across all 50 states. The platform's patient-centric design removes every barrier for patients to start and stay on therapy and delivers significant lift for brands: on average, 52% more patient starts and 41% more fills per patient. With Operation Access Now, the initiative enables: Rapid Stand‑Up: DTP programs that can be operational in as little as 21 days, thanks to BlinkRx's turnkey platform and flexible rules engine. Future-Proof: A modular platform that allows pharmaceutical manufacturers to start with a DTP solution and expand into future capabilities as needs and regulations change. For example, the platform can be deployed for DTB models, and can service both cashpay and insurance patients. Scale: Unique automation capabilities that enable pharmaceutical manufacturers to effortlessly scale based on patient demand and adoption. Legacy DTP solutions, such as copay cards and standalone cash pharmacies, are often costly, inefficient, and prone to patient and physician frustration- causing delays in access, misuse, and poor experiences. BlinkRx's platform addresses these ecosystem issues while ensuring strict regulatory compliance. "Operation Access Now is about removing every barrier between manufacturers and the patients who need their therapies," said Geoffrey Chaiken, Co‑Founder and CEO of BlinkRx. "We're prepared to enable manufacturers to deploy DTP programs and deliver the speed, scale, and flexibility the market demands." About BlinkRx BlinkRx is a Prescription Lifecycle Management Platform that allows the most innovative Life Sciences companies to design every aspect of the prescription journey to unlock branded medication affordability and access for all Americans. Learn more at View source version on Contacts For media inquiries, please contact: Press@
Yahoo
28 minutes ago
- Yahoo
Crocs Sinks Most Since March 2020 on Tariffs, Cautious Consumers
(Bloomberg) -- Crocs Inc. shares dropped the most since the start of the Covid-19 pandemic on a weaker outlook, with the maker of colorful clogs warning that cautious consumers are further pulling back on spending. All Hail the Humble Speed Hump Mayor Asked to Explain $1.4 Billion of Wasted Johannesburg Funds Three Deaths Reported as NYC Legionnaires' Outbreak Spreads Major Istanbul Projects Are Stalling as City Leaders Sit in Jail PATH Train Service Resumes After Fire at Jersey City Station Third-quarter revenue will decline approximately 9% to 11%, the company said on Thursday, well below analysts' average estimate for a gain of less than 1%. On Crocs' earnings call with analysts, executives said they won't reinstate full-year guidance, which it first withdrew earlier this year, due to changing global trade policies. The stock fell as much as 29% in Thursday trading in New York, the most since March 2020. The drop pushed the shares' year-to-date decline to nearly 30%, versus a 7.7% increase for the Russell 3000 Index. Chief Executive Officer Andrew Rees said US consumers, faced with price increases, are behaving 'cautiously around discretionary spending.' This 'has the potential to be a further drag on an already choiceful consumer,' he added. 'They're not even going to the stores and we see traffic down,' he said, adding the current conditions are preventing the company from raising prices to compensate for the impact of tariffs on countries where Crocs produces footwear. Crocs joins companies such as Steve Madden Ltd. and Lululemon Athletica Inc. that have been hit simultaneously by economic uncertainty and higher tariffs on nations such as China, which produces a large volume of apparel and footwear. In the three months ended March 31, Crocs reported that China produced around 22% of products send to the US — a percentage the company plans to reduce. A 'predominant portion' of merchandise also comes from Vietnam, Indonesia, India and Cambodia. Crocs is focusing on managing its expenses through cost cuts, inventory reduction and fewer promotions. 'Crocs might have a tougher time navigating tariff pressures, given its decision to pull back on promotions to preserve brand image,' Bloomberg Intelligence analyst Abigail Gilmartin said in a note. --With assistance from Katerina Petroff and Micah Barkley. (Updates with conference call detail and shares trading.) The Pizza Oven Startup With a Plan to Own Every Piece of the Pie Russia's Secret War and the Plot to Kill a German CEO AI Flight Pricing Can Push Travelers to the Limit of Their Ability to Pay A High-Rise Push Is Helping Mumbai Squeeze in Pools, Gyms and Greenery Government Steps Up Campaign Against Business School Diversity ©2025 Bloomberg L.P. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
